The combination of papillary thyroid microcarcinoma and diffuse toxic goiter in a patient with acromegaly

Acromegaly is a severe multifactorial neuroendocrine disease accompanied by increased secretion of growth hormone, which contributes to the active proliferation of cells of various tissues in the body. Among the complications of the disease, cardiovascular pathology predominates, and is often the cause of increased mortality. Recently, however, with acromegaly, cases of detection of thyroid cancer are increasingly described. The causes and increasing prevalence of benign and malignant neoplasms of the thyroid gland in patients with acromegaly cause much debate in the medical world. The American Thyroid Association guidelines do not include acromegaly in the list of conditions with an increased risk of thyroid cancer but a number of experimental and epidemiological data indicate a high likelihood of such complications. We present a clinical case of diagnosed papillary thyroid cancer in a patient with acromegaly.

1. Gasperi m, martino e, manetti l, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an italian multi-center study. J endocrinol invest. 2002;25(3):240-245. Doi:10.1007/bf03343997

2. Tita p, ambrosio mr, scollo c, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin endocrinol (oxf). 2005;63(2):161-167. Doi:10.1111/j.1365-2265.2005.02316

3. Uchoa hb, lima ga, corrêa ll, et al. Prevalence of thyroid diseases in patients with acromegaly: experience of a brazilian center. Arq bras endocrinol metabol. 2013;57(9):685-690. Doi:10.1590/s0004-27302013000900003

4. Cankurtaran y, örük gg, tozduman b. Evaluation of thyroid disease and thyroid malignancy in acromegalic patients [published online ahead of print, 2021 may 14]. Minerva endocrinol (torino). 2021;10.23736/s2724-6507.21.03363-7. Doi:10.23736/s2724-6507.21.03363-7

5. Miyauchi a, ito y. Conservative surveillance management of low-risk papillary thyroid microcarcinoma. Endocrinol metab clin north am. 2019; 48(1):215-226. Https://doi.org/10.1016/j.ecl.2018.10.007

6. Luo y, zhao y, chen k, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J endocrinol invest. 2019;42(2):227-236. Https://doi.org/10.1007/s40618-018-0908-y

7. Page c, biet a, boute p, et al. ‘aggressive papillary’ thyroid microcarcinoma. Eur arch oto-rhino-laryngol. 2009;266(12):1959-1963. Https://doi.org/10.1007/s00405-009-0952-5

8. Yang l, tan z, li y, zhang x, wu y, xu b, wang m. Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the stat3 pathway. J clin lab anal. 2020 dec; 34(12):e23531. Doi: 10.1002/jcla.23531. Epub 2020 aug 26. Pmid: 32851683; pmcid: pmc7755808.

9. Pidchenko ns, krasnoselskyi mv, mitriaieva na, grebenik lv, astapieva om, grushka gv, paskevych oi, fedulenkova yy, myroshnychenk ms. Insulin-like growth factors in the serum of patients with papillary thyroid cancer. Wiad lek. 2021; 74 (8):1925-1930. Pmid: 34537745.

10. Lawnicka h, motylewska e, borkowska m, kuzdak k, siejka a, swietoslawski j, stepien h, stepien t. Elevated serum concentrations of igf-1 and igf-1r in patients with thyroid cancers. Biomed pap med fac univ palacky olomouc czech repub. 2020 mar; 164 (1):77-83. Doi: 10.5507/bp.2019.018. Epub 2019 may 23. Pmid: 31132076.

11. Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, et al. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23:879–84 ; Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. Br J Cancer. 2010;102:1397–9 ; Kwon, H., Moon, BI. Prognosis of papillary thyroid cancer in patients with Graves’ disease: a propensity score-matched analysis. World J Surg Onc 18, 266 (2020). https://doi.org/10.1186/s12957-020-02044-x

12. Staniforth JU, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves’ disease: a meta-analysis. Int J Surg. 2016;27:118–25

13. Medas F, Erdas E, Canu GL, Longheu A, Pisano G, Tuveri M, et al. Does hyperthyroidism worsen prognosis of thyroid carcinoma? A retrospective analysis on 2820 consecutive thyroidectomies. J Otolaryngol Head Neck Surg. 2018;47:6

14. Dias Lopes NM, Mendonca Lens HH, Armani A, Marinello PC, Cecchini AL. Thyroid cancer and thyroid autoimmune disease: a review of molecular aspects and clinical outcomes. Pathol Res Pract. 2020;216(9):153098 ; Yoshioka W, Miyauchi A, Ito M, Kudo T, Tamai H, Nishihara E, et al. Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves’ disease. Endocr J. 2016;63(2):179–85.]